Arvinas to Present at May 2024 Investor Conferences

NEW HAVEN, Conn., May 02, 2024 — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company at the clinical stage, is pioneering a novel type of drugs based on the principle of targeted protein degradation. The company recently disclosed its participation in two significant investor conferences this May.

On May 14, Arvinas will attend the BofA Securities 2024 Healthcare Conference in Las Vegas. The company's Chief Medical Officer, Noah Berkowitz, M.D., Ph.D., and Chief Business Officer, Randy Teel, Ph.D., are scheduled to engage in a fireside chat at 3:00 p.m. PT. For those interested, a live audio webcast of their presentation will be accessible through the company's website.

Following this, on May 21, Arvinas will take part in the UBS Spring Biotech Conferences. During this event, Berkowitz and Teel will participate in one-on-one meetings with investors.

Arvinas is a clinical-stage biotech enterprise focused on enhancing the lives of patients afflicted by severe and life-threatening diseases. Their mission revolves around the discovery, development, and commercialization of therapeutic solutions designed to degrade proteins that cause diseases. Central to their approach is the proprietary PROTAC® Discovery Engine platform. This platform facilitates the creation of proteolysis targeting chimeras, known as PROTAC® targeted protein degraders. These degraders are engineered to utilize the body's own protein disposal system to selectively and efficiently eliminate disease-causing proteins.

The company's pipeline is notably robust, featuring both preclinical and clinical-stage programs. Among the clinical-stage programs are four investigational therapies. Vepdegestrant (ARV-471) is aimed at treating patients with locally advanced or metastatic ER+/HER2- breast cancer. ARV-766 and bavdegalutamide target the treatment of men suffering from metastatic castration-resistant prostate cancer. Additionally, ARV-102 is under investigation for the treatment of patients with neurodegenerative disorders.

The innovative approach taken by Arvinas, particularly their use of the PROTAC® Discovery Engine platform, has the potential to revolutionize the treatment of various debilitating diseases. By harnessing the body’s natural mechanisms for protein degradation, the company hopes to offer new hope to patients for whom traditional therapies may not be effective.

Arvinas continues to forge ahead in the biotech landscape, driven by a commitment to translating scientific discoveries into real-world medical solutions. Their upcoming participation in these key investor conferences underscores their active engagement with the investment community and their ongoing efforts to push the boundaries of medical science.